Ken Griffin Seelos Therapeutics, Inc. Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$0.66 - $259.46 $141,065 - $55.5 Million
-213,736 Reduced 95.95%
9,011 $6,000
Q3 2022

Nov 14, 2022
SELL
$0.65 - $278.68 $302,456 - $130 Million
-465,317 Reduced 67.63%
222,747 $229,000
Q2 2022

Aug 15, 2022
BUY
$0.51 - $0.93 $320,482 - $584,409
628,397 Added 1053.17%
688,064 $468,000
Q1 2022

May 16, 2022
BUY
$0.84 - $1.71 $34,400 - $70,029
40,953 Added 218.84%
59,667 $50,000
Q4 2021

Feb 14, 2022
SELL
$1.59 - $2.38 $81,597 - $122,139
-51,319 Reduced 73.28%
18,714 $30,000
Q3 2021

Nov 15, 2021
BUY
$1.69 - $2.89 $38,452 - $65,756
22,753 Added 48.12%
70,033 $169,000
Q2 2021

Aug 16, 2021
SELL
$2.64 - $6.32 $200,727 - $480,528
-76,033 Reduced 61.66%
47,280 $124,000
Q1 2021

May 17, 2021
BUY
$1.35 - $4.99 $61,423 - $227,040
45,499 Added 58.47%
123,313 $592,000
Q4 2020

Feb 16, 2021
BUY
$0.74 - $2.01 $42,442 - $115,283
57,355 Added 280.34%
77,814 $123,000
Q3 2020

Nov 16, 2020
BUY
$0.6 - $1.25 $12,275 - $25,573
20,459 New
20,459 $19,000
Q2 2020

Aug 14, 2020
SELL
$0.42 - $1.51 $14,889 - $53,529
-35,450 Closed
0 $0
Q1 2020

May 15, 2020
BUY
$0.47 - $1.56 $10,473 - $34,761
22,283 Added 169.23%
35,450 $17,000
Q2 2019

Aug 14, 2019
BUY
$2.11 - $3.3 $27,782 - $43,451
13,167 New
13,167 $29,000

Others Institutions Holding SEEL

# of Institutions
1
Shares Held
40.5K
Call Options Held
0
Put Options Held
0
View Full List

About SEELOS THERAPEUTICS, INC.

SEEL Quotes by TradingView
  • Ticker SEEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 106,691,000
  • Market Cap $32M
  • Description
  • Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in...
More about SEEL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email